The Balance Between the Therapeutic Efficacy and Safety of [ 177 Lu]Lu-NeoB in a Preclinical Prostate Cancer Model.

Lu]Lu-NeoB is effective in a preclinical PCa model. Adjusting the administered dose could positively impact the risk-benefit balance as a higher dose might not lead to an increased therapeutic effect, but it may lead to an increase in toxicological effects in healthy organs such as the kidneys.